AstraZeneca’s Tagrisso plus chemotherapy wins EU approval for NSCLC
Pharmaceutical Technology
JULY 5, 2024
Approval is based on positive data from the Phase III FLAURA2 trial where Tagrisso plus chemotherapy showed PFS of 24.4 months.
Fri.Jul 05, 2024
246 
NeuroSense Therapeutics shares positive results of lead candidate in ALS
Pharma Times
JULY 5, 2024
The neurodegenerative disease currently affects more than 200,000 people worldwide
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Innovent sells its share in CAR T-cell therapy to IASO Bio for 18% equity
Pharmaceutical Technology
JULY 5, 2024
Fucaso, a BCMA CAR T-cell therapy, is co-developed by Innovent and IASO Bio and was approved to treat multiple myeloma in China last month.
Study reveals mobile phone data can help map the spread of pathogens
Pharma Times
JULY 5, 2024
Pneumococcus is the leading cause of pneumonia, meningitis and sepsis worldwide
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
BioSenic to extend US patent for ATO use in sepsis treatment
Pharmaceutical Technology
JULY 5, 2024
BioSenic and Medsenic filed patent application with the USPTO to extend the protection for the use of arsenic trioxide (ATO) for sepsis.
Innovation in generics: Increased efficiency through peptide API synthesis expertise
pharmaphorum
JULY 5, 2024
Discover how innovative approaches and specialised expertise in peptide API synthesis are increasing efficiency and driving advancements in the manufacturing of Active Pharmaceutical Ingredients (API).
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Labour, the NHS, and life sciences: Partnerships and people
pharmaphorum
JULY 5, 2024
Explore the vital partnerships and people involved in shaping Labour's policies on the NHS, healthcare, and life sciences during the general election. Learn more about the key areas of focus and priorities.
EAN 2024: sublingual apomorphine better tolerated by dopamine agonist users
Pharmaceutical Technology
JULY 5, 2024
SL-APO is marketed by Bial in France, Germany, Spain and the UK for the on-demand treatment of leveodopa wear-off.
Private equity firms ‘eyeing $20bn for Sanofi consumer unit’
pharmaphorum
JULY 5, 2024
Reports indicate that private equity firms Bain Capital and Cinven may be contemplating a bid for the consumer health division of Sanofi.
EMA validates Philogen and Sun Pharma’s MAA for melanoma
Pharmaceutical Technology
JULY 5, 2024
The EMA has validated Philogen and Sun Pharmaceutical’s marketing authorisation application (MAA) for Nidlegy, a treatment for melanoma.
NHS will take more than one term to fix, says Streeting
pharmaphorum
JULY 5, 2024
After Labour landslide in UK general election, former shadow health secretary West Streeting sets out his objectives for the NHS.
How will a Labour government support the UK clinical trials industry?
Pharmaceutical Technology
JULY 5, 2024
The UK took to the polls on 4 July 2024 and voted in a new government. How will a Labour government look for the clinical trial sector?
Single-cell multi-omics and oncological potential
pharmaphorum
JULY 5, 2024
Learn about Professor Melanie Bailey's research on single-cell multi-omics and its oncological potential through the company SEISMIC. Discover the groundbreaking work and contributions to the field.
Dupixent “addresses current gap” in COPD biologics landscape
Pharmaceutical Technology
JULY 5, 2024
Whilst Regeneron and Sanofi secured approval in Europe for COPD, the FDA has delayed Dupixent’s application review for the disease in the US.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
The Omentum Project - a frank and honest discussion with two time ovarian cancer survivor, Meg Wilkinson
Outsourcing Pharma
JULY 5, 2024
Meg Wilkinson, a resilient cancer survivor, recently sat down with OSP editor Liza Laws to discuss her journey from diagnosis to founding the Omentum Project.
New Labour government backs pharma reform in UK
Pharmaceutical Technology
JULY 5, 2024
As the UK transitions into a Labour party government, the pharma industry urges for boosted investment and talent attraction.
Which pharmaceutical drugs have the most drug patents in Denmark?
Drug Patent Watch
JULY 5, 2024
This chart shows the drugs with the most patents in Denmark. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.
CAN-3110 by Candel Therapeutics for High-Grade Glioma: Likelihood of Approval
Pharmaceutical Technology
JULY 5, 2024
CAN-3110 is under clinical development by Candel Therapeutics and currently in Phase I for High-Grade Glioma.
New tentative approval for Alembic drug dabigatran etexilate mesylate
Drug Patent Watch
JULY 5, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.
CTX-310 by CRISPR Therapeutics for Hypertriglyceridemia: Likelihood of Approval
Pharmaceutical Technology
JULY 5, 2024
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Hypertriglyceridemia.
New patent expiration for Abbvie drug ORILISSA
Drug Patent Watch
JULY 5, 2024
Annual Drug Patent Expirations for ORILISSA Orilissa is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug.
CTX-310 by CRISPR Therapeutics for Heterozygous familial hypercholesterolemia (heFH): Likelihood of Approval
Pharmaceutical Technology
JULY 5, 2024
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Heterozygous familial hypercholesterolemia (heFH).
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
New patent for Medicines360 drug LILETTA
Drug Patent Watch
JULY 5, 2024
Annual Drug Patent Expirations for LILETTA Liletta is a drug marketed by Medicines360 and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.
CTX-310 by CRISPR Therapeutics for Homozygous Familial Hypercholesterolemia (HoFH): Likelihood of Approval
Pharmaceutical Technology
JULY 5, 2024
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Homozygous Familial Hypercholesterolemia (HoFH).
New patent for Deciphera Pharms drug QINLOCK
Drug Patent Watch
JULY 5, 2024
Annual Drug Patent Expirations for QINLOCK Qinlock is a drug marketed by Deciphera Pharms and is included in one NDA. It is available from one supplier.
AZD-2389 by AstraZeneca for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Pharmaceutical Technology
JULY 5, 2024
AZD-2389 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Empower Cancer Survivors and Caregivers: Join This Study!
Trialfacts
JULY 5, 2024
Contents About the Study Why Participate? Your Rights Who Can Participate? More Study Details About the Research Center Research Center: The University of Arizona College of Nursing Location: This virtual study is open to the United States Lead Researchers: Chris Segrin, PhD and Terry Badger, PhD, RN IRB: This study has been reviewed and approved by the University of Arizona Institutional Review Board An Institutional Review Board responsible for human subjects research at The University of Ariz
NN-6561 by Novo Nordisk for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Pharmaceutical Technology
JULY 5, 2024
NN-6561 is under clinical development by Novo Nordisk and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Comparing Bariatric Metabolic Surgery, Glucagon-Like Peptide-1 Receptor Agonists Mortality Among Patients with Obesity and Diabetes
Pharmaceutical Commerce
JULY 5, 2024
An observational, retrospective cohort study undergoes this investigation in individuals 24 years of age or older.
Dalfampridine IR by Solaxa for Spinocerebellar Ataxia (SCA): Likelihood of Approval
Pharmaceutical Technology
JULY 5, 2024
Dalfampridine IR is under clinical development by Solaxa and currently in Phase II for Spinocerebellar Ataxia (SCA).
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content